Abstract
Purpose
We conducted a network meta-analysis of randomized controlled trials comparing the efficacy and safety of multiple endovascular treatments for femoropopliteal lesions.
Methods
Nine treatments for femoropopliteal lesions were identified. We compared major amputation and all-cause mortality at 12-month follow-ups and primary patency at 6-, 12- and 24-month follow-ups of the treatments.
Results
Altogether, 26 studies (52 study arms; 4102 patients) were considered eligible. In terms of primary patency, drug-eluting stent (DES) placement was the most effective treatment at 6- and 12-month follow-ups and covered stent (CS) placement at 24-month follow-ups, whereas directional atherectomy (DA) was the least effective treatment during all follow-up periods; both DES and CS placements were better than the majority of other single treatments, including balloon angioplasty, DA, nitinol stent (NS) placement and drug-coated balloon use, during all follow-up periods. In terms of 12-month major amputation and all-cause mortality, DA was the most safe treatment, whereas NS placement was the least safe single treatment.
Conclusions
DES and CS placements have shown encouraging results in terms of primary patency for femoropopliteal lesions, DES placement performs better within 12 months after operation and CS placement at approximately 24 months, while DA seems to be less effective. DA may be better than other treatments in terms of major amputation and all-cause mortality, while NS seems to be less safe.
Similar content being viewed by others
References
Konstantinos K, Stavros S, Narayan K, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59:1123–33.
Christos K, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr Cardiol Rev. 2009;5:296–311.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5–67.
Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). J Vasc Surg. 2011;54:e32–58.
Antonopoulos CN, Mylonas SN, Moulakakis KG, et al. A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg. 2016;65:234.
Xiao Y, Chen Z, Yang Y, et al. Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease. Diagn Interv Radiol. 2016;22:436–43.
Higgins J, Altman D, Gotzsche P, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:5928.
Graudal N, Hubeck-Graudal T, Tarp S, et al. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS ONE. 2014;9:e106408.
Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and bayesian network meta-analysis of randomized controlled trial. J Endovasc Ther. 2016;23:851.
Vroegindeweij D, Tielbeek AV, Buth J, et al. Directional atherectomy versus balloon angioplasty in segmental femoropopliteal artery disease: two-year follow-up with color-flow duplex scanning. J Vasc Surg. 1995;21:255–68.
Shammas NW, Coiner D, Shammas GA, et al. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol. 2011;22:1223–8.
Zeller T, Langhoff R, Rocha-Singh KJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency. Circ Cardiovasc Interv. 2017;10:e004848.
Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;47:239.
Laird J, Katzen B, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.
Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.
Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–9.
Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090–5.
Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions: a randomized controlled study. Int Angiol. 1999;18:251–5.
Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Interv Radiol. 2013;36:353–61.
Rastan A, Krankenberg H, Baumgartner I, et al. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation. 2013;127:2535–41.
Rastan A, Krankenberg H, Baumgartner I, et al. Stent placement versus balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. J Endovasc Ther. 2015;22:22–7.
Poncyljusz W, Falkowski A, Safranow K, et al. Cutting-balloon angioplasty versus balloon angioplasty as treatment for short atherosclerotic lesions in the Superficial femoral artery: randomized controlled trial. Cardiovasc Interv Radiol. 2013;36:1500–7.
Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320–7.
Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Interv Radiol. 2015;38:25–32.
Saxon RR, Dake MD, Volgelzang RL, et al. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19:823–32.
Saxon RR, Coffman JM, Gooding JM, et al. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol. 2003;14:303–11.
Jia X, Zhang JW, Zhuang BX, et al. Acotec drug-coated balloon catheter randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9:1941–9.
Scheinert D, Schulte KL, Zeller T, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–302.
Tepe G, Gogebakan O, Redlich U, et al. Angiographic and clinical outcomes after treatment of femoropopliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. Cardiovasc Interv Radiol. 2017;40:1–10.
Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.
Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12 month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions. J Am Coll Cardiol. 2015;66:2329–38.
Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized pacifier trial. Circ Cardiovasc Interv. 2012;5:831–40.
Krishnan P, Faries P, Niazi K, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102–13.
Schroeder H, Werner M, Meyer DR, et al. Low-dose paclitaxel-coated Versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: 1 year results of the ILLUMENATE European randomized clinical trial. Circulation. 2017;135:2227–36.
Bausback Y, Willfort-Ehringer A, Sievert H, et al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24:459–67.
Steiner S, Willfort-Ehringer A, Sievert H, et al. Twelve-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11:934–41.
Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9.
Rosenfield K, Jaff MR, White CJ. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. J Vasc Surg. 2016;63:846.
Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2 year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–27.
Moher D, Liberati A, Tetzlaff J. Methods of systematic reviews and meta-analysis preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Jaff MR, Nelson T, Ferko N, et al. Endovascular interventions for femoropopliteal peripheral artery disease: a network meta-analysis of current technologies. J Vasc Interv Radiol. 2017;28:1617–27.
Sofia D, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33:607–17.
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80–97.
Zhou Y, Lin S, Zhang Z, et al. A network meta-analysis of randomized controlled trials comparing treatment modalities for infrapopliteal lesions in critical limb ischemia. Ann Vasc Surg. 2019;60C:391–401.
Funding
This study was funded by Medical Research Project of Guangdong Province, China (Grant Numbers A2012254), providing funding that was used to pay for the editing and publication fees. The funding sources were not involved in the study design; collection, analysis or interpretation of the data; writing of the report; or decision to submit the article for publication.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
For this type of study, formal consent is not required.
Informed Consent
For this type of study, informed consent is not required.
Consent for Publication
For this type of study, consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
Plots of the surface under the cumulative ranking curves (SUCRAs) for primary patency. BA, balloon angioplasty; CS, covered stent; DA, directional atherectomy; DA-DCB, directional atherectomy with drug-coated balloon; DCB, drug-coated balloon; DES, drug-eluting stent; NS, nitinol stent (TIFF 7055 kb)
Supplementary Fig. 2
Comparison-adjusted funnel plot for all outcome measures. The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. Different colors correspond to different comparisons. BA, balloon angioplasty; CB, cutting balloon; CS, covered stent; DA, directional atherectomy; DA-DCB, directional atherectomy with drug-coated balloon; DCB, drug-coated balloon; DES, drug-eluting stent; NS, nitinol stent; NS-DCB, nitinol stent with drug-coated balloon (TIFF 6027 kb)
Supplementary Fig. 3
Plots of the surface under the cumulative ranking curves (SUCRAs) for major amputation. BA, balloon angioplasty; CB, cutting balloon; CS, covered stent; DA, directional atherectomy; DA-DCB, directional atherectomy with drug-coated balloon; DCB, drug-coated balloon; DES, drug-eluting stent; NS, nitinol stent; NS-DCB, nitinol stent with drug-coated balloon (TIFF 2076 kb)
Supplementary Fig. 4
Plots of the surface under the cumulative ranking curves (SUCRAs) for all-cause mortality. BA, balloon angioplasty; CB, cutting balloon; CS, covered stent; DA, directional atherectomy; DA-DCB, directional atherectomy with drug-coated balloon; DCB, drug-coated balloon; DES, drug-eluting stent; NS, nitinol stent; NS-DCB, nitinol stent with drug-coated balloon (TIFF 2076 kb)
Rights and permissions
About this article
Cite this article
Zhou, Y., Zhang, Z., Lin, S. et al. Comparative Efficacy and Safety of Endovascular Treatment Modalities for Femoropopliteal Artery Lesions: A Network Meta-analysis of Randomized Controlled Trials. Cardiovasc Intervent Radiol 43, 204–214 (2020). https://doi.org/10.1007/s00270-019-02332-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-019-02332-4